Blockade of chemokine signaling in patients with multiple sclerosis

F. Zipp; H. P. Hartung; J. Hillert; S. Schimrigk; C. Trebst; M. Stangel; C. Infante-Duarte; P. Jakobs; C. Wolf; R. Sandbrink; C. Pohl; M. Filippi

doi:10.1212/01.wnl.0000244420.68037.86

Blockade of chemokine signaling in patients with multiple sclerosis

F. Zipp, H. P. Hartung, J. Hillert, S. Schimrigk, C. Trebst, M. Stangel, C. Infante-Duarte, P. Jakobs, C. Wolf, R. Sandbrink, C. Pohl, M. Filippi

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.

Original language	English
Pages (from-to)	1880-1883
Number of pages	4
Journal	Neurology
Volume	67
Issue number	10
DOIs	https://doi.org/10.1212/01.wnl.0000244420.68037.86
Publication status	Published - Nov 2006

ASJC Scopus subject areas

Neuroscience(all)

Access to Document

10.1212/01.wnl.0000244420.68037.86

Cite this

@article{4a775d76ccd14752955ad441d640253c,

title = "Blockade of chemokine signaling in patients with multiple sclerosis",

abstract = "We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.",

author = "F. Zipp and Hartung, {H. P.} and J. Hillert and S. Schimrigk and C. Trebst and M. Stangel and C. Infante-Duarte and P. Jakobs and C. Wolf and R. Sandbrink and C. Pohl and M. Filippi",

year = "2006",

month = nov,

doi = "10.1212/01.wnl.0000244420.68037.86",

language = "English",

volume = "67",

pages = "1880--1883",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Blockade of chemokine signaling in patients with multiple sclerosis

AU - Zipp, F.

AU - Hartung, H. P.

AU - Hillert, J.

AU - Schimrigk, S.

AU - Trebst, C.

AU - Stangel, M.

AU - Infante-Duarte, C.

AU - Jakobs, P.

AU - Wolf, C.

AU - Sandbrink, R.

AU - Pohl, C.

AU - Filippi, M.

PY - 2006/11

Y1 - 2006/11

N2 - We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.

AB - We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.

UR - http://www.scopus.com/inward/record.url?scp=33845458609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845458609&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000244420.68037.86

DO - 10.1212/01.wnl.0000244420.68037.86

M3 - Article

C2 - 17130431

AN - SCOPUS:33845458609

SN - 0028-3878

VL - 67

SP - 1880

EP - 1883

JO - Neurology

JF - Neurology

IS - 10

ER -

Blockade of chemokine signaling in patients with multiple sclerosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this